Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ELYM - Eliem Therapeutics Inc


IEX Last Trade
7.02
-0.340   -4.843%

Share volume: 1,109,057
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$7.36
-0.34
-4.62%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
16.50%
1 Month
-14.13%
3 Months
-8.75%
6 Months
154.19%
1 Year
157.93%
2 Year
129.93%
Key data
Stock price
$7.02
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$2.35 - $11.55
52 WEEK CHANGE
$1.64
MARKET CAP 
468.751 M
YIELD 
N/A
SHARES OUTSTANDING 
67.060 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$414,071
AVERAGE 30 VOLUME 
$265,806
Company detail
CEO:
Region: US
Website: eliemtx.com
Employees: 11
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

eliem therapeutics is a biotechnology company delivering therapies that empower patients to live on their own terms. headquartered in seattle with r&d primarily in cambridge, uk, eliem channels its experience, energy, and passion for improving patients’ quality of life by developing and commercializing potentially “best-in-class” drug candidates to treat neuronal excitability disorders. these conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. at its core, the eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. eliem is a publicly traded company (nasdaq: elym) read our community guidelines here: https://eliemtx.com/community-engagement-guidelines/

Recent news